-+ 0.00%
-+ 0.00%
-+ 0.00%

Cypherpunk unit Leap Therapeutics reports DeFianCe Phase 2 sirexatamab results published in Clinical Cancer Research

PUBT·08/12/2026 11:03:48
Listen to the news
Cypherpunk unit Leap Therapeutics reports DeFianCe Phase 2 sirexatamab results published in Clinical Cancer Research
  • Cypherpunk Technologies’ biotech unit Leap Therapeutics published Phase 2 DeFianCe results for sirexatamab in Clinical Cancer Research.
  • Analyses tied higher baseline plasma DKK1 to greater sirexatamab benefit in second-line metastatic colorectal cancer, supporting a biomarker-selected Phase 3 plan.
  • In DKK1-high patients above the median, response rate rose to 38% from 23.7%; median PFS improved to 9 months from 7.1 months.
  • Upper-quartile DKK1 patients showed the largest effect, with median OS not reached vs 9.5 months; hazard ratio 0.17.
  • Primary PFS endpoint in the overall intent-to-treat group was not met; median PFS was 9.2 months vs 8.3 months.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cypherpunk Technologies Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608120700PR_NEWS_USPR_____NE24369) on August 12, 2026, and is solely responsible for the information contained therein.